Can BAP1 expression loss in mesothelial cells be an indicator of malignancy?
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Malignant mesothelioma is a highly aggressive tumor that can be confused with a benign mesothelial lesion, especially cytomorphologic lesions. BRCA1-associated protein 1 (BAP1) acts as a tumor suppressor. In this study, we aim to investigate the value of BAP1 staining of malignant mesothelioma cases with expression loss and diagnosis in cell block and biopsy tissue. Methods: Between January 2009 and March 2017, 64 mesotheliomas, 117 reactive mesothelial hyperplasias, and 20 fibrinous pleuritis/pericarditis were diagnosed with morphologic and immunohistochemical findings in our pathology clinic and were included in the study. Formalin-fixed, paraffin-embedded tissues were immunohistochemically examined for BAP1. Inflammatory and stromal cells were used as positive internal controls. BAP1 was assessed for nuclear staining in mesothelial cells. Results: Examinations of the relationship between patient diagnosis and BAP1 biopsy status showed that the BAP1 loss rate (76.6%) was significantly higher in malignant mesothelioma cases than in other benign diseases (0%) (p < .001). Sensitivity and specificity were 76.56% and 100%, respectively, for biopsy tissue from malignant mesothelioma. Sensitivity and specificity were both 100% for BAP1 test on cell block tissue. Furthermore, the consistency between BAP1 cell block and biopsy results was excellent (ĸ = 0.90) and the correlation was significant (p < .001). Conclusions: This study shows that BAP1 expression loss in both cytology and biopsy tissue in biopsy-confirmed malignant mesothelioma cases is an essential parameter for malignant mesothelioma diagnosis.
Abstract
Background: Malignant mesothelioma is a highly aggressive tumor that can be confused with a benign mesothelial lesion, especially cytomorphologic lesions. BRCA1-associated protein 1 (BAP1) acts as a tumor suppressor. In this study, we aim to investigate the value of BAP1 staining of malignant mesothelioma cases with expression loss and diagnosis in cell block and biopsy tissue. Methods: Between January 2009 and March 2017, 64 mesotheliomas, 117 reactive mesothelial hyperplasias, and 20 fibrinous pleuritis/pericarditis were diagnosed with morphologic and immunohistochemical findings in our pathology clinic and were included in the study. Formalin-fixed, paraffin-embedded tissues were immunohistochemically examined for BAP1. Inflammatory and stromal cells were used as positive internal controls. BAP1 was assessed for nuclear staining in mesothelial cells. Results: Examinations of the relationship between patient diagnosis and BAP1 biopsy status showed that the BAP1 loss rate (76.6%) was significantly higher in malignant mesothelioma cases than in other benign diseases (0%) (p < .001). Sensitivity and specificity were 76.56% and 100%, respectively, for biopsy tissue from malignant mesothelioma. Sensitivity and specificity were both 100% for BAP1 test on cell block tissue. Furthermore, the consistency between BAP1 cell block and biopsy results was excellent (ĸ = 0.90) and the correlation was significant (p < .001). Conclusions: This study shows that BAP1 expression loss in both cytology and biopsy tissue in biopsy-confirmed malignant mesothelioma cases is an essential parameter for malignant mesothelioma diagnosis.
참고문헌 (23)
- Cagle PT, "Pathology of the pleura : what the pulmonologists need to know", Respirology, 16, pp.430~438 (2011)
- Carbone M, "The pathogenesis of mesothelioma", Semin Diagn Pathol, 23, pp.56~60 (2006)
- Hicks J, "Biologic, cytogenetic, and molecular factors in mesothelial proliferations", Ultrastruct Pathol, 30, pp.19~30 (2006)
- Hida T, "Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis : comparison with 9p21 FISH and BAP1 immunohistochemistry", Lung Cancer, 104, pp.98~105 (2017)
- Kushitani K, "Utility of survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia", Oncol Lett, 15, pp.3540~3547 (2018)
- Lee HE, "BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma", Hum Pathol, 79, pp.168~176 (2018)
- Baris YI, "Environmental mesothelioma in Turkey", Ann N Y Acad Sci, 330, pp.423~432 (1979)
- Cagle PT, "Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies", Arch Pathol Lab Med, 129, pp.1421~1427 (2005)
- King J, "Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease : a systematic review of published reports", Histopathology, 49, pp.561~568 (2006)
- Kradin RL, "Distinguishing benign mesothelial hyperplasia from neoplasia : a practical approach", Semin Diagn Pathol, 23, pp.4~14 (2006)
- Attanoos RL, "The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium : a novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, Pglycoprotein and Bcl-2", Histopathology, 43, pp.231~238 (2003)
- Mayall FG, "The frequency of p53 immunostaining in asbestos-associated mesotheliomas and non-asbestos-associated mesotheliomas", Histopathology, 22, pp.383~386 (1993)
- Taheri ZM, "The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations", Arch Pathol Lab Med, 132, pp.694~697 (2008)
- Pulford E, "Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA : does BAP1 have potential for early diagnosis and assessment of prognosis", Dis Markers, 2017, pp.1310478~ (2017)
- McGregor SM, "BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A(p16)fluorescence in situ hybridization in malignant pleural mesothelioma", Hum Pathol, 60, pp.86~94 (2017)
- LaFave LM, "Loss of BAP1 function leads to EZH2-dependent transformation", Nat Med, 21, pp.1344~1349 (2015)
- Shinozaki-Ushiku A, "Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma", Histopathology, 70, pp.722~733 (2017)
- Cozzi I, "Loss of BRCA1-associated protein 1(BAP1)expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions", Diagn Cytopathol, 46, pp.9~14 (2018)
- Cigognetti M, "BAP1(BRCA1-associated protein 1)is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations", Mod Pathol, 28, pp.1043~1057 (2015)
- Walts AE, "BAP1 Immunostain and CDKN2A(p16)FISH analysis : clinical applicability for the diagnosis of malignant mesothelioma in effusions", Diagn Cytopathol, 44, pp.599~606 (2016)
- Wu D, "Usefulness of p16", CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma, 2017, pp.26, 31~37
- Hjerpe A, "Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma : a secondary publication", Cytopathology, 26, pp.142~156 (2015)
- Onder S, "Diagnostic value of BRCA1-associated protein-1, glucose transporter-1and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions", Cytopathology, 30, pp.592~600 (2019)